The dose of the oral anticoagulant may need to be adjusted during atovaquone/proguanil treatment or after its withdrawal, based on INR results.Concomitant treatment with tetracycline has been associated with decreases in plasma concentrations of atovaquone.The co-administration of atovaquone at doses of 45 mg/kg/day in children (n=9) with acute lymphoblastic leukaemia for prophylaxis of PCP was found to increase the plasma concentrations (AUC) of etoposide and its metabolite etoposide catechol by a median of 8.6% (P=0.055) and 28.4% (P=0.031) (respectively compared to the co-administration of etoposide and sulfamethoxazole-trimethoprim). In non-immune subjects, the average duration of exposure in clinical studies was 27 days.One Atovaquone/Proguanil Hydrochloride film-coated tablet daily.Atovaquone/Proguanil Hydrochloride is not recommended for malaria prophylaxis in persons under 40 kg bodyweight.
By continuing to browse the site you are agreeing to our policy on the use of cookies. Atovaquone plus Proguanil (Malarone™) Atovaquone-proguanil (AP; see the previous discussion) is an attractive agent for emergency self-treatment, provided the traveler is not taking this agent for prophylaxis. 2. MedicineNet does not provide medical advice, diagnosis or treatment. Atovaquone/proguanil has been shown to have no efficacy against hypnozoites of Parasitaemia should be closely monitored in patients receiving concurrent tetracycline (see section 4.5). In the event of diarrhoea, normal dosing should be continued. The individual components have shown no effects on parturition or pre- and post-natal development. The mean oral clearance in paediatric and adult patients weighing 10 to 80 kg ranged from 0.8 to 10.8 L/h for atovaquone and from 15 to 106 L/h for proguanil. In patients with severe renal impairment, the elimination half lives for proguanil (tIn patients with mild to moderate hepatic impairment there is no clinically significant change in exposure to atovaquone when compared to patients with normal hepatic function.In patients with mild to moderate hepatic impairment there is an 85% increase in proguanil AUC with no change in elimination half life and there is a 65-68% decrease in CNo data are available in patients with severe hepatic impairment (see section 4.2).Findings in repeat dose toxicity studies with atovaquone-proguanil hydrochloride combination were entirely proguanil related and were observed at doses providing no significant margin of exposure in comparison with the expected clinical exposure. However, as with other antimalarial agents, subjects with diarrhoea or vomiting should be advised to continue with malaria prevention measures by complying with personal protection measures (repellants, impregnated bednets). This medication contains 2 medicines: atovaquone and proguanil. Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. The daily dose should be taken with food or a milky drink (to ensure maximum absorption of atovaquone) at the same time each day. The following convention is used for the classification of frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to There are limited long-term safety data in children.

This contains the same active ingredients as Malarone and is a fully licensed UK medicine. No data are available regarding the effects of the combination on fertility or pre- and post-natal development, but studies on the individual components of atovaquone-proguanil film-coated tablets have shown no effects on these parameters. Studies have shown that atovaquone and proguanil hydrochloride is safe and effective for prevention of falciparum malaria in lifelong residents of malaria-endemic countries, but little is known about non-immune travellers. Continue typing to refine. The following table provides a summary of adverse reactions that have been reported to have a suspected (at least possible) causal relationship to treatment with atovaquone/proguanil in clinical trials and spontaneous post-marketing reports.
It is used to prevent and treat malaria caused by mosquito bites in countries where malaria is common. It contains two active ingredients, atovaquone and proguanil, and is used to treat and prevent malaria. Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with atovaquone/proguanil in patients on continuous treatment with oral anticoagulants. Another antiemetic treatment should be given.When given with efavirenz or boosted protease-inhibitors, atovaquone concentrations have been observed to decrease as much as 75%. Caution should be advised in patients receiving concomitant therapy with etoposide (see section 4.4).Proguanil is primarily metabolised by CYP2C19. Systemic availability of cycloguanil is higher in the elderly compared to the young patients (AUC is increased by 140% and CIn patients with mild to moderate renal impairment, oral clearance and/or AUC data for atovaquone, proguanil and cycloguanil are within the range of values observed in patients with normal renal function. There are no clinical data indicating that folate supplementation diminishes drug efficacy. Malaria symptoms include fever, chills, nausea, vomiting, and body aches. For prophylaxis of P. falciparum malaria in patients with several renal impairments see Section 4.3. In The antimalarial activity of proguanil is exerted via the primary metabolite cycloguanil (There are no pharmacokinetic interactions between atovaquone and proguanil at the recommended dose.